Laurie Letvak

5.2k citations
31 papers · 1.0k · h-index 14

Impact in

  • Hematology top 1%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 2%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 25
    • Chronic Myeloid Leukemia Treatments 23
    • Acute Myeloid Leukemia Research 3
  • Genetics 20
    • Chronic Lymphocytic Leukemia Research 17
    • Glioma Diagnosis and Treatment 2
Co-authors
Jörge E. Cortes (17 shared papers)Hagop M. Kantarjian (16 shared papers)Mary Beth Rios (4 shared papers)Stefan Faderl (9 shared papers)Francis J. Giles (7 shared papers)Guillermo Garcia‐Manero (7 shared papers)Moshe Talpaz (3 shared papers)Alessandra Ferrajoli (5 shared papers)
Journals
Blood (17 papers)Journal of Clinical Oncology (6 papers)Cancer (2 papers)Anti-Cancer Drugs (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
Partner nations
United StatesSwitzerlandGermany

In The Last Decade

Laurie Letvak

31 papers receiving 989 citations

Peers

Laurie Letvak
Comparison fields: 5 of 57
  • Hematology 753
  • Genetics 474
  • Rheumatology 416
  • Oncology 140
  • Public Health, Environmental and Occupational Health 105
Replace Jesper Stentoft with:
Jesper Stentoft Denmark
Manuel Ayala Mexico
Jiří Mayer Czechia
Jenny Shan United States
Nathalie Cambier France
Marianne Rosamilia Switzerland
Eva Löfvenberg Sweden
Agnès Guerci‐Bresler France
Giulia Benevolo Italy
Jean Michel Cayuela France
Laurie Letvak relative to Jesper Stentoft Denmark Jesper Stentoft's profile →
Citations per field
00.5×1.7×
Jesper Stentoft · 1×
Citations per year

Countries citing papers authored by Laurie Letvak

Since Specialization
Citations

This map shows the geographic impact of Laurie Letvak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurie Letvak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurie Letvak more than expected).

Fields of papers citing papers by Laurie Letvak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurie Letvak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurie Letvak. The network helps show where Laurie Letvak may publish in the future.

Co-authors

The 25 scholars most cited alongside Laurie Letvak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurie Letvak Line = papers co-authored together Laurie Letvak links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#Work
1
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
Blood ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Francis J. Giles, Mary Beth Rios, Jianqin Shan, Laurie Letvak, Deborah A. Thomas, Stefan Faderl, Alessandra Ferrajoli, Jörge E. Cortes
2003310
2
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah Thomas, Sima Jeha, Mary Beth Rios, Laurie Letvak, Kathy Bochinski, Ralph B. Arlinghaus, Moshe Talpaz
2002131
3
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
Blood ·Jörge E. Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William G. Wierda, Mary Beth Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop M. Kantarjian
2003120
4
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders
Cancer ·Jörge E. Cortes, Francis J. Giles, Susan O’Brien, Deborah A. Thomas, Maher Albitar, Mary Beth Rios, Moshe Talpaz, Guillermo Garcia‐Manero, Stefan Faderl, Laurie Letvak, August J. Salvado, Hagop M. Kantarjian
200385
5
Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study
Journal of Clinical Oncology ·Paula M. Fracasso, Mark F. Brady, David H. Moore, Joan L. Walker, Peter G. Rose, Laurie Letvak, Thomas M. Grogan, William P. McGuire
200182
6
Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).
Blood ·Jörge E. Cortes, Susan O’Brien, Elias Jabbour, Alexandra Ferrajoli, Gautam Borthakur, Jan A. Burger, William G. Wierda, Guillermo Garcia‐Manero, Michelle Thomas, Laurie Letvak, Hagop M. Kantarjian
200747
7
Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib
Cancer ·Florian H. Heidel, Jörge E. Cortes, Frank G. Rücker, Walter E. Aulitzky, Laurie Letvak, Thomas Kindler, Christoph Huber, Hartmut Döhner, Hagop M. Kantarjian, Thomas Fischer
200739
8
Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP)
Journal of Clinical Oncology ·Jörge E. Cortes, Susan O’Brien, A. Ferrajoli, G. Borthakur, Jacobus W. A. Burger, WG Wierda, G. García-Manero, Laurie Letvak, Hagop M. Kantarjian
200830
9
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Blood ·Deborah A. Thomas, Hagop M. Kantarjian, Jörge E. Cortes, Stefan Faderl, Francis J. Giles, Guillermo Garcia‐Manero, William G. Wierda, Alessandra Ferrajoli, Farhad Ravandi‐Kashani, Srđan Verstovšek, Michael Andreeff, Laurie Letvak, Dan Jones, Richard E. Champlin, Susan O’Brien
200620
10
14-Day Continuous Infusion of Mitoxantrone in Hormone-Refractory Metastatic Adenocarcinoma of the Prostate
American Journal of Clinical Oncology ·Philip W. Kantoff, Caroline Block, Laurie Letvak, M. George
199320
11
Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Blood ·Deborah A. Thomas, Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Stefan Faderl, Dan Jones, Laurie Letvak, Partow Kebriaei, Richard E. Champlin, Susan O’Brien
200817
12
PSC833: initial clinical results in refractory ovarian cancer patients.
PubMed ·Abbie L. Fields, Howard S. Höchster, Carolyn D. Runowicz, James L. Speyer, Gary L. Goldberg, C Cohen, Peter R. Dottino, Scott Wadler, G.I. Berk, H. Gretz, J. Mandeli, (unknown), Laurie Letvak
199817
13
Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Blood ·Deborah A. Thomas, Stefan Faderl, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Guillermo García, Steven M. Kornblau, Michael Andreeff, Miloslav Beran, Srđan Verstovšek, Sherry Pierce, Laurie Letvak, August J. Salvado, Richard E. Champlin, Hagop M. Kantarjian
200414
14
Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
Blood ·Jörge E. Cortes, Susan O’Brien, Dan Jones, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Guillermo Garcia‐Manero, Laurie Letvak, Hagop M. Kantarjian
200814
15
Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).
Blood ·Elias Jabbour, Jörge E. Cortes, Francis J. Giles, Susan O’Brien, Laurie Letvak, Hagop Kantarjian
200612
16
Safety and Efficacy of I‐Leucovorin Rescue Following High‐Dose Methotrexate for Osteosarcoma
Medical and Pediatric Oncology ·Allen M. Goorin, Douglas Strother, David G. Poplack, Laurie Letvak, Martine George, Michael P. Link
199512
17
Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Blood ·Deborah A. Thomas, Hagop M. Kantarjian, Farhad Ravandi, Stefan Faderl, Guillermo Garcia‐Manero, William G. Wierda, Alessandra Ferrajoli, Srđan Verstovšek, Dan Jones, Laurie Letvak, Richard E. Champlin, Jörge E. Cortes, Susan O’Brien
20078
18
Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)
Journal of Clinical Oncology ·Elias Jabbour, F. Giles, Jörge E. Cortes, Sheila O'brien, Farhad Ravandi, G. Borthakur, G. Garcia‐Manero, Laurie Letvak, August J. Salvado, Hagop M. Kantarjian
20068
19
Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)
Journal of Clinical Oncology ·D. A. Thomas, Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Stefan Faderl, David Jones, Laurie Letvak, Richard Champlin, Susan O’Brien
20087
20
Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma
Anti-Cancer Drugs ·Norman Jafte, Keith Jorgensen, Resa Robertson, Martine George, Laurie Letvak, G. S. Barrett
19935

About Laurie Letvak

Laurie Letvak is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Rheumatology and Pulmonary and Respiratory Medicine, having authored 31 papers that have together received 1.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (17 papers), Acute Lymphoblastic Leukemia research (13 papers), Eosinophilic Disorders and Syndromes (6 papers), Acute Myeloid Leukemia Research (3 papers), Glioma Diagnosis and Treatment (2 papers), Click Chemistry and Applications (1 paper) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Hematology (753 citations), Genetics (474 citations), Rheumatology (416 citations), Oncology (140 citations) and Public Health, Environmental and Occupational Health (105 citations). Laurie Letvak has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Mary Beth Rios, Stefan Faderl, Francis J. Giles, Guillermo Garcia‐Manero, Moshe Talpaz, Alessandra Ferrajoli, Deborah A. Thomas and Susan O’Brien. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Anti-Cancer Drugs and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jesper StentoftBreakdown of academic impact, for papers by Manuel AyalaBreakdown of academic impact, for papers by Jiří MayerBreakdown of academic impact, for papers by Jenny ShanBreakdown of academic impact, for papers by Nathalie CambierBreakdown of academic impact, for papers by Marianne RosamiliaBreakdown of academic impact, for papers by Eva LöfvenbergBreakdown of academic impact, for papers by Agnès Guerci‐BreslerBreakdown of academic impact, for papers by Giulia BenevoloBreakdown of academic impact, for papers by Jean Michel Cayuela